← Back to Search

PET/CT Imaging Agent for COVID-19

Phase < 1

Waitlist Available

Research Sponsored by University of California, Davis

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosed with SARS CoV2

Able to remain motionless for up to 30-60 minutes per scan.

Must not have

Other active infectious respiratory illness

Women who are pregnant or breast-feeding

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

No Placebo-Only Group

Summary

This trial is studying a PET/CT imaging agent to see if it can help in finding and measuring damage caused by SARS CoV2 infection.

Who is the study for?

This trial is for men and women over 18 who had COVID-19 but are now negative, with no prior lung diseases. They must have had a lung image taken during their infection and be able to stay still for up to an hour per scan. It's not for those with other respiratory infections, pregnant or breastfeeding women, patients too heavy for PET/CT scans (>350lbs), or anyone unlikely to attend follow-up sessions.

What is being tested?

The study tests a new imaging agent called 18F-αvβ6-binding-peptide in PET/CT scans on patients who've recovered from COVID-19. The goal is to see how well this peptide works in detecting changes in the lungs after SARS-CoV-2 infection.

What are the potential side effects?

Potential side effects of the imaging agent used in this trial are not detailed here; however, common side effects from similar agents may include allergic reactions, injection site pain, or temporary discomfort during scanning.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with COVID-19.

Select...

I can stay still for up to an hour.

Select...

I had no lung conditions before my COVID-19 infection.

Select...

I have had two COVID negative tests before each scan.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I do not have any active infections in my lungs.

Select...

I am not pregnant or breast-feeding.

Select...

I weigh more than 350lbs and cannot have a PET/CT scan.

Select...

I have been re-infected with COVID-19 between scans.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Administration of 18F-αvβ6-BP

Secondary study objectives

Determine whether 18F-αvβ6-BP demonstrates accumulation in lung damage

Other study objectives

Determine whether 18F-αvβ6-BP accumulation in lung correlates to lung damage as indicated on CT.

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: 18F-αvβ6-BPExperimental Treatment1 Intervention

Following a 10 mCi (±20%) intravenous injection (IV) of 18F-αvβ6-BP, PET/CT images will be acquired at 60 minutes. Baseline blood samples will be drawn and banked. Vital sign (VS) measurements (heart rate, respiratory rate, blood pressure and temperature) monitored throughout. Region-of-interest analysis (ROI) will be performed in the lung. Each participant will undergo up to 3 18F- αvβ6-BP PET/CT scans over a 6-month timeframe.

0 / 8Eligibility criteria met